Achondroplasia is driven by overactive FGFR3 signaling that disrupts normal growth plate function. The panel explains how this molecular pathway affects endochondral bone growth and provides the foundation for understanding targeted treatment.
Back
Advancing Care in Achondroplasia: From Diagnosis to Clinical Evidence and Patient-Centered Care
A pediatric endocrinologist, a complex care pediatrician, and a clinical geneticist trace achondroplasia from its FGFR3 origins through diagnosis and skeletal and airway complications to the growing menu of CNP-pathway and investigational therapies, closing with guidance on monitoring, care coordination, and the patient advocacy organizations that support families long-term.
Advancing Care in Achondroplasia: From Diagnosis to Clinical Evidence and Patient-Centered Care
Episodes
All
All
Characteristic clinical and radiographic findings can establish early suspicion for achondroplasia, while molecular and prenatal testing are helping clinicians confirm the diagnosis sooner.
Advertisement
Advertisement
Trending on HCPLive
1
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
2
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
3
FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes
4
Immediate Coronary Angiography Does Not Improve Survival Outcomes in Cardiac Arrest
5